NCT06505837View on ClinicalTrials.gov

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

395

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
Interventions
DRUG

JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy

The combination therapy of JS001sc and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001sc and pemetrexed maintenance therapy, and the cumulative treatment of JS001sc did not exceed 35 cycles (Each cycle is 21 days).

DRUG

JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy

The combination therapy of JS001 and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001 and pemetrexed maintenance therapy, and the cumulative treatment of JS001 did not exceed 35 cycles (Each cycle is 21 days).

Trial Locations (1)

410013

Hunan Cancer Hospital, Changshang

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT06505837 - JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） | Biotech Hunter | Biotech Hunter